# NivoMes (NCT02497508)

> Nivolumab in Patients With Recurrent Malignant Mesothelioma

No report yet. It can be ordered.

- Drugs tested: nivolumab
- Indication: recurrent malignant pleural mesothelioma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02497508
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: The Netherlands Cancer Institute
- Conditions: Malignant Pleural Mesothelioma
- Interventions: nivolumab
- Enrollment: 33
- Primary outcome: DCR

## Indexed commentary on NivoMes so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 9 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nivomes-nct02497508

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02497508", "email": "<work email>"}; the inbox owner confirms by the emailed link.